Intravenous sodium valproate for acute migraine in the emergency department: A meta‐analysis. (25th August 2020)

• Record Type: Journal Article
• Authors: Wang, Fengzhi; Zhang, Hemin; Wang, Liyu; Cao, Yumeng; He, Qiu
• Is Part Of: Acta neurologica Scandinavica. Volume 142:Number 6(2020)
• Page Start: 521
• Page End: 530
• Publication Date: 2020-08-25
• Subjects: emergency department -- headache -- migraine -- sodium valproate; Neurology -- Periodicals; 616.8
• DOI: 10.1111/ane.13325
• Languages: English
• ISSNs: 0001-6314

Abstract

Abstract : The role of intravenous sodium valproate (iVPA) in acute migraine attack has not been completely established. The aim of this updated review was to evaluate the efficacy and safety of iVPA in patients with acute migraine in the emergency department. We searched the PubMed, Web of Science, and Cochrane Library databases for relevant randomized controlled trials (RCTs). The primary outcome was improvement of headache intensity and headache relief. The need for rescue therapy, recurrence of headache, and number of adverse events was also assessed. Seven double‐blinded RCTs involving 682 patients were analyzed. Overall, patients receiving iVPA had less improvement of headache intensity (SMD: −0.39, 95% CI: −0.73 to −0.06, P = .02) and lower rate of headache relief (OR: 0.51, 95% CI: 0.33 to 0.77, P = .002) than those receiving other active comparators. In addition, iVPA increased the odds of rescue therapy compared with other active drugs (OR: 3.76; 95% CI: 1.96 to 7.20, P < .0001). Subgroup analysis showed that iVPA was comparable to dexamethasone, with similar improvement of headache intensity, and recurrence of headache. For migraine without aura, we found no significant difference in headache intensity improvement when iVPA was compared with active comparators (SMD: −0.00, 95% CI: −0.54 to 0.54, P = 1.00). iVPA was inferior to the studied comparators and was comparable to dexamethasone for aborting migraine attack. Based on the available evidence, iVPA may be a reasonable alternative or salvage therapy. In particular, iVPA might be a promising agent for migraine with aura and migraine status.